<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484197</url>
  </required_header>
  <id_info>
    <org_study_id>CIDD001A2201</org_study_id>
    <secondary_id>2011-001825-25</secondary_id>
    <nct_id>NCT01484197</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device</brief_title>
  <official_title>A Multi-centre, Randomized, Double-blind, Double-dummy, Multiple-dose, Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered as Either PulmoSphere or Lactose-blend Powder Via the Concept1 Device in Adult Patients With Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two
      different formulations of indacaterol maleate, both administered via the Concept1 device. The
      study aims to determine whether the novel formulation has a similar clinical profile as the
      established formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment</measure>
    <time_frame>Day 8</time_frame>
    <description>Spirometry was performed according to internationally accepted standards at Day 8. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose.at Day 8. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1) After 1 Day of Treatment</measure>
    <time_frame>Day 2</time_frame>
    <description>Spirometry was performed according to internationally accepted standards at Day 2. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose at Day 2. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 at Day 1 and Day 7</measure>
    <time_frame>Day 1, Day 7</time_frame>
    <description>Spirometry was performed according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after 1 day of treatment and on Day 7 and Day 8 following 7 days of treatment. Peak FEV1 was the maximum FEV1 post treatment. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak FEV1 at Day 1 and Day 7</measure>
    <time_frame>Day 1, Day 7</time_frame>
    <description>Spirometry was performed according to internationally accepted standards. Time to the peak (maximum) FEV1 is recorded. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at Each Time-Point on Day 1 and Day 2</measure>
    <time_frame>Day 1, Day 2</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8, 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 at Each Time-Point on Day 7 and Day 8</measure>
    <time_frame>Day 7, Day 8</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at Each Time-Point on Day 1 and Day 2</measure>
    <time_frame>Day 1, Day 2</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) at Each Time-Point on Day 7 and Day 8</measure>
    <time_frame>Day 7, Day 8</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC at Each Post-Dose Time Point on Day 1 and Day 2</measure>
    <time_frame>Day1, Day 2</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC at Each Post-dose Time Point on Day 7 and Day 8</measure>
    <time_frame>Day 7, Day 8</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after treatment. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 1 and Day 2</measure>
    <time_frame>Day 1, Day 2</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 7 and Day 8</measure>
    <time_frame>Day 7, Day 8</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized FEV1 AUC Between Baseline (Pre-dose) and 4 Hour Post-dose (AUC0-4h)</measure>
    <time_frame>Day 1, Day 7</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards at predose, 5, 15 and 30 minutes, 1, 2 and 4 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 4 h post. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized FEV1 AUC Between Baseline (Pre-dose) and 12 Hour Post-dose (AUC0-12h)</measure>
    <time_frame>Day 1, Day 7</time_frame>
    <description>Spirometry was conducted according to internationally accepted standards at predose, 5 , 15 and 30 min, 1, 2, 4, 8 and 12 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post. Analysis of covariance with treatment, period, sequence and subject nested within sequence as fixed effects and FEV1 period baseline as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate in the Morning in the Evening</measure>
    <time_frame>Up to 101 days</time_frame>
    <description>PEFR was measured on all days from Screening Visit 2 to end of study visit: twice daily pre-dose (prior to Inhaled Corticosteroids) and approximately 12 hours post-dose (during the treatment period). Each subject was provided with a PEFR meter and recorded the PEFR readings in a daily diary. repeated measures. Analysis of covariance with treatment, period, sequence, day and treatment-day interaction as fixed effect and subject as a random effect and baseline PEFR as a covariate in the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Puffs of Rescue Medicine</measure>
    <time_frame>Up to 101 days</time_frame>
    <description>Salbutamol (100 µg/puff) was used as rescued medicine. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient and was recorded in the patient diary from Baseline until Day 8 of Treatment Period 4. Analysis of covariance with treatment, period, sequence, and subject nested within sequence as fixed effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety</measure>
    <time_frame>Up to 101 days</time_frame>
    <description>Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards. Additional information about adverse events can be found in the Adverse Event section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) After Drug Administration</measure>
    <time_frame>Day1, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax) After Drug Administration</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Pre-dose to 24 Hour Post Dose (AUC0-24h)</measure>
    <time_frame>Day 1, Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>75 µg Indacaterol (LB) + Placebo (PoS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>37.5 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (LB) and Placebo (PoS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 µg indacaterol maleate (LB)</intervention_name>
    <description>75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
    <arm_group_label>75 µg Indacaterol (LB) + Placebo (PoS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 µg indacaterol maleate (PoS)</intervention_name>
    <description>75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.</description>
    <arm_group_label>75 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>37.5 µg indacaterol maleate (PoS)</intervention_name>
    <description>37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.</description>
    <arm_group_label>37.5 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to indacaterol (LB)</intervention_name>
    <description>Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
    <arm_group_label>75 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
    <arm_group_label>37.5 µg Indacaterol (PoS) + Placebo (LB)</arm_group_label>
    <arm_group_label>Placebo (LB) and Placebo (PoS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to indacaterol (PoS)</intervention_name>
    <description>Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.</description>
    <arm_group_label>75 µg Indacaterol (LB) + Placebo (PoS)</arm_group_label>
    <arm_group_label>Placebo (LB) and Placebo (PoS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with asthma

          -  Aged 18 or above

          -  Patients using inhaled corticosteroid (with or without long acting beta agonist)

          -  Patients who demonstrate an increase in FEV1 after inhaling a short acting beta
             agonist

        Exclusion Criteria:

          -  Asthma exacerbations in previous 6 months

          -  COPD or other pulmonary disease

          -  Excessive use of short acting beta agonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Machester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <results_first_submitted>May 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2013</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Indacaterol</keyword>
  <keyword>QAB149</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Treatment Period 1: 75 µg indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacaterol (lactose blend) + 75 µg indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacaterol (lactose blend) + 37.5 µg Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Treatment Period 1: placebo to indacaterol (lactose blend) + 75 µg indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: 75 µg indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM ) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacaterol (lactose blend) + 37.5 µg Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Treatment Period 1: placebo to indacaterol (lactose blend) + 37.5 µg Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacaterol (lactose blend) + 75 µg indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: 75 µg indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Treatment Period 1: placebo to indacterol (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 2: placebo to indacaterol (lactose blend) + 37.5 µg Indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 3: 75 µg indacaterol maleate (lactose blend) + placebo to indacterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. Treatment Period 4: placebo to indacaterol (lactose blend) + 75 µg indacaterol (PulmoSphereTM) delivered via the Concept1 device once daily in the morning for 7 days. All participants took part in a 7 day run-in period. There was a minimum 14 day washout between each treatment period. Participants continued their current treatment with Inhaled corticosteroids. Inhaled short-acting B2-agonist salbutamol was available for use as rescue medication throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7">1 patient completed Period 1 but did not enter Period 2 due to a Protocol deviation.</participants>
                <participants group_id="P2" count="8">1 patient completed Period 1 but did not enter Period 2 due to an Adverse event (AE).</participants>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6">2 patients completed Period 3 but did not enter Period 4 due to a Protocol deviation and an AE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants randomized to one of four treatment sequences.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment</title>
        <description>Spirometry was performed according to internationally accepted standards at Day 8. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose.at Day 8. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment</title>
          <description>Spirometry was performed according to internationally accepted standards at Day 8. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose.at Day 8. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="0.03"/>
                    <measurement group_id="O2" value="2.83" spread="0.03"/>
                    <measurement group_id="O3" value="2.80" spread="0.03"/>
                    <measurement group_id="O4" value="2.64" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1) After 1 Day of Treatment</title>
        <description>Spirometry was performed according to internationally accepted standards at Day 2. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose at Day 2. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
        <time_frame>Day 2</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1) After 1 Day of Treatment</title>
          <description>Spirometry was performed according to internationally accepted standards at Day 2. Trough FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Trough FEV1 was defined as the average of the FEV1 measurements at 23 hours 10 minutes and 23 hours 45 minutes post dose at Day 2. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.03"/>
                    <measurement group_id="O2" value="2.84" spread="0.03"/>
                    <measurement group_id="O3" value="2.81" spread="0.03"/>
                    <measurement group_id="O4" value="2.62" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 at Day 1 and Day 7</title>
        <description>Spirometry was performed according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after 1 day of treatment and on Day 7 and Day 8 following 7 days of treatment. Peak FEV1 was the maximum FEV1 post treatment. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline included as a covariate.</description>
        <time_frame>Day 1, Day 7</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 at Day 1 and Day 7</title>
          <description>Spirometry was performed according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after 1 day of treatment and on Day 7 and Day 8 following 7 days of treatment. Peak FEV1 was the maximum FEV1 post treatment. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline included as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="3.04" upper_limit="3.13"/>
                    <measurement group_id="O2" value="3.11" lower_limit="3.07" upper_limit="3.16"/>
                    <measurement group_id="O3" value="3.05" lower_limit="3.01" upper_limit="3.10"/>
                    <measurement group_id="O4" value="2.85" lower_limit="2.80" upper_limit="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,30,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="3.05" upper_limit="3.13"/>
                    <measurement group_id="O2" value="3.11" lower_limit="3.06" upper_limit="3.15"/>
                    <measurement group_id="O3" value="3.10" lower_limit="3.06" upper_limit="3.14"/>
                    <measurement group_id="O4" value="2.89" lower_limit="2.85" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak FEV1 at Day 1 and Day 7</title>
        <description>Spirometry was performed according to internationally accepted standards. Time to the peak (maximum) FEV1 is recorded. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
        <time_frame>Day 1, Day 7</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak FEV1 at Day 1 and Day 7</title>
          <description>Spirometry was performed according to internationally accepted standards. Time to the peak (maximum) FEV1 is recorded. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" lower_limit="0.25" upper_limit="23.77"/>
                    <measurement group_id="O2" value="3.02" lower_limit="0.25" upper_limit="23.75"/>
                    <measurement group_id="O3" value="3.00" lower_limit="0.25" upper_limit="23.75"/>
                    <measurement group_id="O4" value="3.00" lower_limit="0.25" upper_limit="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,30,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.22" upper_limit="23.82"/>
                    <measurement group_id="O2" value="3.05" lower_limit="0.25" upper_limit="23.77"/>
                    <measurement group_id="O3" value="3.00" lower_limit="0.98" upper_limit="23.78"/>
                    <measurement group_id="O4" value="3.97" lower_limit="0.25" upper_limit="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at Each Time-Point on Day 1 and Day 2</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8, 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
        <time_frame>Day 1, Day 2</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at Each Time-Point on Day 1 and Day 2</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8, 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="0.71"/>
                    <measurement group_id="O2" value="2.65" spread="0.70"/>
                    <measurement group_id="O3" value="2.68" spread="0.68"/>
                    <measurement group_id="O4" value="2.67" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="0.76"/>
                    <measurement group_id="O2" value="2.97" spread="0.80"/>
                    <measurement group_id="O3" value="2.90" spread="0.75"/>
                    <measurement group_id="O4" value="2.66" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.76"/>
                    <measurement group_id="O2" value="2.96" spread="0.75"/>
                    <measurement group_id="O3" value="2.93" spread="0.73"/>
                    <measurement group_id="O4" value="2.70" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.76"/>
                    <measurement group_id="O2" value="3.03" spread="0.80"/>
                    <measurement group_id="O3" value="2.95" spread="0.75"/>
                    <measurement group_id="O4" value="2.73" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.73"/>
                    <measurement group_id="O2" value="3.06" spread="0.81"/>
                    <measurement group_id="O3" value="3.02" spread="0.74"/>
                    <measurement group_id="O4" value="2.82" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.76"/>
                    <measurement group_id="O2" value="3.09" spread="0.80"/>
                    <measurement group_id="O3" value="3.05" spread="0.75"/>
                    <measurement group_id="O4" value="2.80" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="0.73"/>
                    <measurement group_id="O2" value="3.07" spread="0.81"/>
                    <measurement group_id="O3" value="3.00" spread="0.75"/>
                    <measurement group_id="O4" value="2.77" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="0.60"/>
                    <measurement group_id="O2" value="2.99" spread="0.83"/>
                    <measurement group_id="O3" value="2.89" spread="0.79"/>
                    <measurement group_id="O4" value="2.70" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.65"/>
                    <measurement group_id="O2" value="2.92" spread="0.79"/>
                    <measurement group_id="O3" value="2.85" spread="0.79"/>
                    <measurement group_id="O4" value="2.71" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="0.74"/>
                    <measurement group_id="O2" value="2.85" spread="0.77"/>
                    <measurement group_id="O3" value="2.83" spread="0.76"/>
                    <measurement group_id="O4" value="2.59" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.75"/>
                    <measurement group_id="O2" value="2.88" spread="0.80"/>
                    <measurement group_id="O3" value="2.85" spread="0.72"/>
                    <measurement group_id="O4" value="2.68" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 at Each Time-Point on Day 7 and Day 8</title>
        <description>Spirometry was conducted according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
        <time_frame>Day 7, Day 8</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 at Each Time-Point on Day 7 and Day 8</title>
          <description>Spirometry was conducted according to internationally accepted standards at 0, 15 and 30 minutes; 1,2,3,4,8,12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="0.77"/>
                    <measurement group_id="O2" value="2.79" spread="0.72"/>
                    <measurement group_id="O3" value="2.85" spread="0.73"/>
                    <measurement group_id="O4" value="2.63" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.80"/>
                    <measurement group_id="O2" value="2.88" spread="0.77"/>
                    <measurement group_id="O3" value="2.92" spread="0.76"/>
                    <measurement group_id="O4" value="2.65" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.79"/>
                    <measurement group_id="O2" value="2.92" spread="0.76"/>
                    <measurement group_id="O3" value="2.94" spread="0.77"/>
                    <measurement group_id="O4" value="2.64" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.75"/>
                    <measurement group_id="O2" value="2.96" spread="0.77"/>
                    <measurement group_id="O3" value="2.97" spread="0.76"/>
                    <measurement group_id="O4" value="2.72" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="0.76"/>
                    <measurement group_id="O2" value="3.00" spread="0.72"/>
                    <measurement group_id="O3" value="3.00" spread="0.73"/>
                    <measurement group_id="O4" value="2.79" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="0.74"/>
                    <measurement group_id="O2" value="2.99" spread="0.75"/>
                    <measurement group_id="O3" value="3.06" spread="0.75"/>
                    <measurement group_id="O4" value="2.79" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.75"/>
                    <measurement group_id="O2" value="2.98" spread="0.73"/>
                    <measurement group_id="O3" value="3.02" spread="0.70"/>
                    <measurement group_id="O4" value="2.78" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="0.64"/>
                    <measurement group_id="O2" value="2.88" spread="0.77"/>
                    <measurement group_id="O3" value="2.89" spread="0.75"/>
                    <measurement group_id="O4" value="2.76" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="0.66"/>
                    <measurement group_id="O2" value="2.80" spread="0.78"/>
                    <measurement group_id="O3" value="2.82" spread="0.76"/>
                    <measurement group_id="O4" value="2.65" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.71"/>
                    <measurement group_id="O2" value="2.79" spread="0.77"/>
                    <measurement group_id="O3" value="2.79" spread="0.79"/>
                    <measurement group_id="O4" value="2.64" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.72"/>
                    <measurement group_id="O2" value="2.87" spread="0.76"/>
                    <measurement group_id="O3" value="2.87" spread="0.74"/>
                    <measurement group_id="O4" value="2.74" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at Each Time-Point on Day 1 and Day 2</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
        <time_frame>Day 1, Day 2</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at Each Time-Point on Day 1 and Day 2</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="1.02"/>
                    <measurement group_id="O2" value="4.30" spread="0.98"/>
                    <measurement group_id="O3" value="4.23" spread="1.03"/>
                    <measurement group_id="O4" value="4.27" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="1.07"/>
                    <measurement group_id="O2" value="4.52" spread="1.10"/>
                    <measurement group_id="O3" value="4.34" spread="1.04"/>
                    <measurement group_id="O4" value="4.25" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="1.03"/>
                    <measurement group_id="O2" value="4.47" spread="1.02"/>
                    <measurement group_id="O3" value="4.39" spread="1.01"/>
                    <measurement group_id="O4" value="4.18" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="1.06"/>
                    <measurement group_id="O2" value="4.49" spread="1.05"/>
                    <measurement group_id="O3" value="4.38" spread="1.06"/>
                    <measurement group_id="O4" value="4.30" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="0.99"/>
                    <measurement group_id="O2" value="4.54" spread="1.07"/>
                    <measurement group_id="O3" value="4.45" spread="1.02"/>
                    <measurement group_id="O4" value="4.36" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="1.04"/>
                    <measurement group_id="O2" value="4.52" spread="1.05"/>
                    <measurement group_id="O3" value="4.44" spread="0.98"/>
                    <measurement group_id="O4" value="4.33" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="1.01"/>
                    <measurement group_id="O2" value="4.54" spread="1.06"/>
                    <measurement group_id="O3" value="4.40" spread="1.01"/>
                    <measurement group_id="O4" value="4.30" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="0.86"/>
                    <measurement group_id="O2" value="4.51" spread="1.09"/>
                    <measurement group_id="O3" value="4.35" spread="1.07"/>
                    <measurement group_id="O4" value="4.21" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="0.93"/>
                    <measurement group_id="O2" value="4.42" spread="1.05"/>
                    <measurement group_id="O3" value="4.29" spread="1.04"/>
                    <measurement group_id="O4" value="4.24" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.06"/>
                    <measurement group_id="O2" value="4.44" spread="1.08"/>
                    <measurement group_id="O3" value="4.31" spread="1.08"/>
                    <measurement group_id="O4" value="4.21" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="1.06"/>
                    <measurement group_id="O2" value="4.41" spread="1.10"/>
                    <measurement group_id="O3" value="4.36" spread="1.08"/>
                    <measurement group_id="O4" value="4.30" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) at Each Time-Point on Day 7 and Day 8</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
        <time_frame>Day 7, Day 8</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) at Each Time-Point on Day 7 and Day 8</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. FVC is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="1.07"/>
                    <measurement group_id="O2" value="4.30" spread="0.93"/>
                    <measurement group_id="O3" value="4.35" spread="1.06"/>
                    <measurement group_id="O4" value="4.22" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.09"/>
                    <measurement group_id="O2" value="4.33" spread="0.95"/>
                    <measurement group_id="O3" value="4.36" spread="1.06"/>
                    <measurement group_id="O4" value="4.21" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="1.08"/>
                    <measurement group_id="O2" value="4.36" spread="0.96"/>
                    <measurement group_id="O3" value="4.37" spread="1.06"/>
                    <measurement group_id="O4" value="4.21" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="1.06"/>
                    <measurement group_id="O2" value="4.35" spread="0.97"/>
                    <measurement group_id="O3" value="4.41" spread="1.05"/>
                    <measurement group_id="O4" value="4.28" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="1.04"/>
                    <measurement group_id="O2" value="4.40" spread="0.90"/>
                    <measurement group_id="O3" value="4.42" spread="1.02"/>
                    <measurement group_id="O4" value="4.37" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="1.01"/>
                    <measurement group_id="O2" value="4.40" spread="0.93"/>
                    <measurement group_id="O3" value="4.46" spread="1.03"/>
                    <measurement group_id="O4" value="4.34" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="1.05"/>
                    <measurement group_id="O2" value="4.39" spread="0.91"/>
                    <measurement group_id="O3" value="4.44" spread="0.99"/>
                    <measurement group_id="O4" value="4.32" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="0.97"/>
                    <measurement group_id="O2" value="4.29" spread="0.94"/>
                    <measurement group_id="O3" value="4.31" spread="1.05"/>
                    <measurement group_id="O4" value="4.31" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="0.98"/>
                    <measurement group_id="O2" value="4.23" spread="0.94"/>
                    <measurement group_id="O3" value="4.25" spread="1.04"/>
                    <measurement group_id="O4" value="4.21" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="1.08"/>
                    <measurement group_id="O2" value="4.30" spread="0.97"/>
                    <measurement group_id="O3" value="4.29" spread="1.08"/>
                    <measurement group_id="O4" value="4.28" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="1.08"/>
                    <measurement group_id="O2" value="4.34" spread="0.97"/>
                    <measurement group_id="O3" value="4.34" spread="1.08"/>
                    <measurement group_id="O4" value="4.36" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC at Each Post-Dose Time Point on Day 1 and Day 2</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
        <time_frame>Day1, Day 2</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC at Each Post-Dose Time Point on Day 1 and Day 2</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.08"/>
                    <measurement group_id="O2" value="0.62" spread="0.08"/>
                    <measurement group_id="O3" value="0.64" spread="0.09"/>
                    <measurement group_id="O4" value="0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.08"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.09"/>
                    <measurement group_id="O4" value="0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.07"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.08"/>
                    <measurement group_id="O4" value="0.65" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.07"/>
                    <measurement group_id="O2" value="0.67" spread="0.07"/>
                    <measurement group_id="O3" value="0.68" spread="0.08"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.08"/>
                    <measurement group_id="O2" value="0.67" spread="0.07"/>
                    <measurement group_id="O3" value="0.68" spread="0.08"/>
                    <measurement group_id="O4" value="0.65" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.08"/>
                    <measurement group_id="O2" value="0.68" spread="0.07"/>
                    <measurement group_id="O3" value="0.69" spread="0.08"/>
                    <measurement group_id="O4" value="0.65" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.08"/>
                    <measurement group_id="O2" value="0.67" spread="0.07"/>
                    <measurement group_id="O3" value="0.68" spread="0.08"/>
                    <measurement group_id="O4" value="0.65" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.07"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.08"/>
                    <measurement group_id="O4" value="0.64" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.08"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.66" spread="0.08"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.09"/>
                    <measurement group_id="O2" value="0.64" spread="0.08"/>
                    <measurement group_id="O3" value="0.66" spread="0.09"/>
                    <measurement group_id="O4" value="0.62" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.08"/>
                    <measurement group_id="O2" value="0.65" spread="0.08"/>
                    <measurement group_id="O3" value="0.66" spread="0.08"/>
                    <measurement group_id="O4" value="0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1/FVC at Each Post-dose Time Point on Day 7 and Day 8</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after treatment. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
        <time_frame>Day 7, Day 8</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1/FVC at Each Post-dose Time Point on Day 7 and Day 8</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2 after treatment. FEV1/FVC ratio is the percentage of the total FVC that is expelled from the lungs during the first second of forced exhalation.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.08"/>
                    <measurement group_id="O2" value="0.65" spread="0.07"/>
                    <measurement group_id="O3" value="0.65" spread="0.08"/>
                    <measurement group_id="O4" value="0.62" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.08"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.07"/>
                    <measurement group_id="O4" value="0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.08"/>
                    <measurement group_id="O2" value="0.67" spread="0.06"/>
                    <measurement group_id="O3" value="0.67" spread="0.07"/>
                    <measurement group_id="O4" value="0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.07"/>
                    <measurement group_id="O2" value="0.68" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.07"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.07"/>
                    <measurement group_id="O2" value="0.68" spread="0.06"/>
                    <measurement group_id="O3" value="0.68" spread="0.07"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.07"/>
                    <measurement group_id="O2" value="0.68" spread="0.07"/>
                    <measurement group_id="O3" value="0.69" spread="0.08"/>
                    <measurement group_id="O4" value="0.65" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.07"/>
                    <measurement group_id="O2" value="0.68" spread="0.07"/>
                    <measurement group_id="O3" value="0.68" spread="0.07"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.07"/>
                    <measurement group_id="O2" value="0.67" spread="0.07"/>
                    <measurement group_id="O3" value="0.67" spread="0.08"/>
                    <measurement group_id="O4" value="0.64" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.08"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.66" spread="0.08"/>
                    <measurement group_id="O4" value="0.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.67"/>
                    <measurement group_id="O2" value="0.65" spread="0.08"/>
                    <measurement group_id="O3" value="0.65" spread="0.08"/>
                    <measurement group_id="O4" value="0.62" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.72"/>
                    <measurement group_id="O2" value="0.66" spread="0.07"/>
                    <measurement group_id="O3" value="0.66" spread="0.08"/>
                    <measurement group_id="O4" value="0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 1 and Day 2</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
        <time_frame>Day 1, Day 2</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 1 and Day 2</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 1 and 23.16 and 23.75 hours on Day 2. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.68"/>
                    <measurement group_id="O2" value="1.52" spread="0.70"/>
                    <measurement group_id="O3" value="1.54" spread="0.67"/>
                    <measurement group_id="O4" value="1.56" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.75"/>
                    <measurement group_id="O2" value="1.81" spread="0.79"/>
                    <measurement group_id="O3" value="1.82" spread="0.77"/>
                    <measurement group_id="O4" value="1.54" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.80"/>
                    <measurement group_id="O2" value="1.82" spread="0.77"/>
                    <measurement group_id="O3" value="1.84" spread="0.73"/>
                    <measurement group_id="O4" value="1.61" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="0.77"/>
                    <measurement group_id="O2" value="1.95" spread="0.85"/>
                    <measurement group_id="O3" value="1.89" spread="0.75"/>
                    <measurement group_id="O4" value="1.59" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.80"/>
                    <measurement group_id="O2" value="1.93" spread="0.84"/>
                    <measurement group_id="O3" value="1.92" spread="0.79"/>
                    <measurement group_id="O4" value="1.68" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.81"/>
                    <measurement group_id="O2" value="2.01" spread="0.83"/>
                    <measurement group_id="O3" value="1.99" spread="0.85"/>
                    <measurement group_id="O4" value="1.68" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.82"/>
                    <measurement group_id="O2" value="1.94" spread="0.85"/>
                    <measurement group_id="O3" value="1.92" spread="0.80"/>
                    <measurement group_id="O4" value="1.65" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.69"/>
                    <measurement group_id="O2" value="1.83" spread="0.84"/>
                    <measurement group_id="O3" value="1.79" spread="0.81"/>
                    <measurement group_id="O4" value="1.59" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.65"/>
                    <measurement group_id="O2" value="1.77" spread="0.78"/>
                    <measurement group_id="O3" value="1.76" spread="0.83"/>
                    <measurement group_id="O4" value="1.61" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.77"/>
                    <measurement group_id="O2" value="1.68" spread="0.75"/>
                    <measurement group_id="O3" value="1.78" spread="0.80"/>
                    <measurement group_id="O4" value="1.51" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="0.74"/>
                    <measurement group_id="O2" value="1.76" spread="0.77"/>
                    <measurement group_id="O3" value="1.75" spread="0.71"/>
                    <measurement group_id="O4" value="1.56" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 7 and Day 8</title>
        <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
        <time_frame>Day 7, Day 8</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow 25- 75% (FEF25-75) on Day 7 and Day 8</title>
          <description>Spirometry was conducted according to internationally accepted standards post-dose at 0, 15 and 30 minutes; 1, 2, 3, 4, 8 and 12 hours on Day 7 and 23.16 and 23.75 hours on Day 8. The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement</population>
          <units>Liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.75"/>
                    <measurement group_id="O2" value="1.69" spread="0.76"/>
                    <measurement group_id="O3" value="1.71" spread="0.78"/>
                    <measurement group_id="O4" value="1.51" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.83"/>
                    <measurement group_id="O2" value="1.78" spread="0.82"/>
                    <measurement group_id="O3" value="1.83" spread="0.80"/>
                    <measurement group_id="O4" value="1.54" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.79"/>
                    <measurement group_id="O2" value="1.80" spread="0.82"/>
                    <measurement group_id="O3" value="1.83" spread="0.81"/>
                    <measurement group_id="O4" value="1.57" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.77"/>
                    <measurement group_id="O2" value="1.89" spread="0.84"/>
                    <measurement group_id="O3" value="1.87" spread="0.80"/>
                    <measurement group_id="O4" value="1.61" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.80"/>
                    <measurement group_id="O2" value="1.89" spread="0.77"/>
                    <measurement group_id="O3" value="1.91" spread="0.82"/>
                    <measurement group_id="O4" value="1.64" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.80"/>
                    <measurement group_id="O2" value="1.88" spread="0.81"/>
                    <measurement group_id="O3" value="2.02" spread="0.82"/>
                    <measurement group_id="O4" value="1.69" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.82"/>
                    <measurement group_id="O2" value="1.88" spread="0.82"/>
                    <measurement group_id="O3" value="1.93" spread="0.83"/>
                    <measurement group_id="O4" value="1.65" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.66"/>
                    <measurement group_id="O2" value="1.80" spread="0.82"/>
                    <measurement group_id="O3" value="1.81" spread="0.82"/>
                    <measurement group_id="O4" value="1.64" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.68"/>
                    <measurement group_id="O2" value="1.68" spread="0.83"/>
                    <measurement group_id="O3" value="1.76" spread="0.83"/>
                    <measurement group_id="O4" value="1.56" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.16 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.67"/>
                    <measurement group_id="O2" value="1.69" spread="0.81"/>
                    <measurement group_id="O3" value="1.68" spread="0.84"/>
                    <measurement group_id="O4" value="1.52" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23.75 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.72"/>
                    <measurement group_id="O2" value="1.73" spread="0.79"/>
                    <measurement group_id="O3" value="1.79" spread="0.76"/>
                    <measurement group_id="O4" value="1.62" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized FEV1 AUC Between Baseline (Pre-dose) and 4 Hour Post-dose (AUC0-4h)</title>
        <description>Spirometry was conducted according to internationally accepted standards at predose, 5, 15 and 30 minutes, 1, 2 and 4 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 4 h post. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
        <time_frame>Day 1, Day 7</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1 AUC Between Baseline (Pre-dose) and 4 Hour Post-dose (AUC0-4h)</title>
          <description>Spirometry was conducted according to internationally accepted standards at predose, 5, 15 and 30 minutes, 1, 2 and 4 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 4 h post. Analysis of Covariance with treatment, period, sequence and subject nested within sequence as fixed effects and period FEV1 baseline as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" lower_limit="2.90" upper_limit="2.99"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.95" upper_limit="3.05"/>
                    <measurement group_id="O3" value="2.94" lower_limit="2.89" upper_limit="2.99"/>
                    <measurement group_id="O4" value="2.72" lower_limit="2.68" upper_limit="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,30,32,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.92" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.98" lower_limit="2.93" upper_limit="3.02"/>
                    <measurement group_id="O3" value="2.97" lower_limit="2.93" upper_limit="3.02"/>
                    <measurement group_id="O4" value="2.73" lower_limit="2.68" upper_limit="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized FEV1 AUC Between Baseline (Pre-dose) and 12 Hour Post-dose (AUC0-12h)</title>
        <description>Spirometry was conducted according to internationally accepted standards at predose, 5 , 15 and 30 min, 1, 2, 4, 8 and 12 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post. Analysis of covariance with treatment, period, sequence and subject nested within sequence as fixed effects and FEV1 period baseline as a covariate.</description>
        <time_frame>Day 1, Day 7</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1 AUC Between Baseline (Pre-dose) and 12 Hour Post-dose (AUC0-12h)</title>
          <description>Spirometry was conducted according to internationally accepted standards at predose, 5 , 15 and 30 min, 1, 2, 4, 8 and 12 hours post-dose on Day 1 and Day 7. The standardized (with respect to the length of time) area under the curve (AUC) for FEV1 was calculated using trapezoidal rule between 5 min and 12 h post. Analysis of covariance with treatment, period, sequence and subject nested within sequence as fixed effects and FEV1 period baseline as a covariate.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="2.85" upper_limit="2.95"/>
                    <measurement group_id="O2" value="2.94" lower_limit="2.89" upper_limit="2.99"/>
                    <measurement group_id="O3" value="2.87" lower_limit="2.82" upper_limit="2.92"/>
                    <measurement group_id="O4" value="2.68" lower_limit="2.63" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=31,29,30,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.88" upper_limit="2.97"/>
                    <measurement group_id="O2" value="2.92" lower_limit="2.88" upper_limit="2.96"/>
                    <measurement group_id="O3" value="2.91" lower_limit="2.87" upper_limit="2.95"/>
                    <measurement group_id="O4" value="2.70" lower_limit="2.66" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow Rate in the Morning in the Evening</title>
        <description>PEFR was measured on all days from Screening Visit 2 to end of study visit: twice daily pre-dose (prior to Inhaled Corticosteroids) and approximately 12 hours post-dose (during the treatment period). Each subject was provided with a PEFR meter and recorded the PEFR readings in a daily diary. repeated measures. Analysis of covariance with treatment, period, sequence, day and treatment-day interaction as fixed effect and subject as a random effect and baseline PEFR as a covariate in the model.</description>
        <time_frame>Up to 101 days</time_frame>
        <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow Rate in the Morning in the Evening</title>
          <description>PEFR was measured on all days from Screening Visit 2 to end of study visit: twice daily pre-dose (prior to Inhaled Corticosteroids) and approximately 12 hours post-dose (during the treatment period). Each subject was provided with a PEFR meter and recorded the PEFR readings in a daily diary. repeated measures. Analysis of covariance with treatment, period, sequence, day and treatment-day interaction as fixed effect and subject as a random effect and baseline PEFR as a covariate in the model.</description>
          <population>Pharmacodynamics Analysis set included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement.</population>
          <units>Liters per second</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.33" spread="2.35"/>
                    <measurement group_id="O2" value="447.15" spread="2.50"/>
                    <measurement group_id="O3" value="444.11" spread="2.47"/>
                    <measurement group_id="O4" value="421.58" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.09" spread="2.18"/>
                    <measurement group_id="O2" value="464.39" spread="2.33"/>
                    <measurement group_id="O3" value="463.28" spread="2.30"/>
                    <measurement group_id="O4" value="433.60" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Puffs of Rescue Medicine</title>
        <description>Salbutamol (100 µg/puff) was used as rescued medicine. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient and was recorded in the patient diary from Baseline until Day 8 of Treatment Period 4. Analysis of covariance with treatment, period, sequence, and subject nested within sequence as fixed effect.</description>
        <time_frame>Up to 101 days</time_frame>
        <population>Participants in the Pharmacodynamics Analysis set (included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement) who used rescue medication.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Puffs of Rescue Medicine</title>
          <description>Salbutamol (100 µg/puff) was used as rescued medicine. The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient and was recorded in the patient diary from Baseline until Day 8 of Treatment Period 4. Analysis of covariance with treatment, period, sequence, and subject nested within sequence as fixed effect.</description>
          <population>Participants in the Pharmacodynamics Analysis set (included all participants that received at least one dose of study drug and had baseline and at least one post-baseline FEV1 measurement) who used rescue medication.</population>
          <units>Puffs/day</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="1.90" upper_limit="2.06"/>
                    <measurement group_id="O2" value="1.90" lower_limit="1.83" upper_limit="1.98"/>
                    <measurement group_id="O3" value="1.91" lower_limit="1.82" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.94" lower_limit="1.87" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety</title>
        <description>Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards. Additional information about adverse events can be found in the Adverse Event section</description>
        <time_frame>Up to 101 days</time_frame>
        <population>Safety population inlcuded all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety</title>
          <description>Adverse event are defined as any unfavorable and unintended diagnosis, symptoms, sign (including an abnormal lab finding), syndrome or disease which either occurs during the study, having been absent at baseline, or if present at baseline appear to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization , cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards. Additional information about adverse events can be found in the Adverse Event section</description>
          <population>Safety population inlcuded all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) After Drug Administration</title>
        <time_frame>Day1, Day 7</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) After Drug Administration</title>
          <population>PK Analysis Set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=31,30,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.22" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.20" upper_limit="0.58"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0.20" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.08" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.22" upper_limit="0.98"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.22" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Concentration (Cmax) After Drug Administration</title>
        <time_frame>Day 1, Day 7</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Concentration (Cmax) After Drug Administration</title>
          <population>PK Analysis Set</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=31,30,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="25.7"/>
                    <measurement group_id="O2" value="124" spread="55.7"/>
                    <measurement group_id="O3" value="64.2" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="27.1"/>
                    <measurement group_id="O2" value="174" spread="61.4"/>
                    <measurement group_id="O3" value="90.5" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Pre-dose to 24 Hour Post Dose (AUC0-24h)</title>
        <time_frame>Day 1, Day 7</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>75 µg Indacaterol (LB)</title>
            <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>75 µg Indacaterol (PoS)</title>
            <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>37.5 µg Indacaterol (PoS)</title>
            <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Pre-dose to 24 Hour Post Dose (AUC0-24h)</title>
          <population>PK Analysis Set</population>
          <units>hour*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=30,30,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501" spread="149"/>
                    <measurement group_id="O2" value="802" spread="308"/>
                    <measurement group_id="O3" value="451" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=33,31,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1110" spread="273"/>
                    <measurement group_id="O2" value="1770" spread="522"/>
                    <measurement group_id="O3" value="952" spread="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The number of participants at risk for serious adverse events and non-serious adverse events is based on those participants in the arm who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>75 µg Indacaterol (LB)</title>
          <description>75 µg indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>75 µg Indacaterol (PoS)</title>
          <description>75 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device daily in the morning for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>37.5 µg Indacaterol (PoS)</title>
          <description>37.5 µg indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device in the morning for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo to indacterol lactose blend or PulmoSphereTM delivered via the Concept1 device in the morning for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Product taste abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

